MTLS (MTLS) Stock Price & Analysis
MTLS (MTLS) rose 0.30% to USD 6.63 as of June 10, 2026 at 02:06 UTC, according to Nexqual real-time market data.
MTLS last closed at USD 6.61; the session ranged USD 6.39–6.83 on volume of 190,334 shares. Market capitalization is $385.73M, with a 52-week range of USD 4.78–7 (NMS). Source: Nexqual, June 10, 2026 at 02:06 UTC.
Key Statistics (as of June 10, 2026 at 02:06 UTC)
| Price | USD 6.63 |
|---|---|
| Change | ▲ 0.30% (up) |
| Previous Close | USD 6.61 |
| Open | USD 6.62 |
| Day Range | USD 6.39 – 6.83 |
| 52-Week Range | USD 4.78 – 7 |
| Volume | 190,334 shares |
| Market Cap | $385.73M |
| Exchange | NMS |
Technical Analysis (MTLS)
Nexqual's technical model rates MTLS "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 02:06 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 63.71 (neutral) |
| vs SMA50 | Above (USD 5.64) |
| MACD | 0.32 (positive) |
Analyst Ratings (MTLS)
Wall Street analysts rate MTLS "Strong Buy" based on 3 analysts, with a mean price target of USD 8.17 (range USD 6.67–9.81), per Nexqual as of June 10, 2026 at 02:06 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 8.17 |
| High Target | USD 9.81 |
| Low Target | USD 6.67 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (MTLS)
| Next Earnings Date | 2026-05-07 |
|---|---|
| EPS Estimate | USD 0.04 |
| Revenue Estimate | $68.50M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.03 vs est 0.01 ▲ beat |
| 2025-12-31 | USD 0.12 vs est 0.06 ▲ beat |
| 2025-09-30 | USD 0.04 vs est 0.01 ▲ beat |
| 2025-06-30 | USD 0.01 vs est 0.02 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:06 UTC.
Financials & Fundamentals (MTLS)
| Total Revenue | $267.53M |
|---|---|
| Revenue Growth (YoY) | -0.20% |
| Gross Margin | +57.61% |
| Operating Margin | +3.15% |
| Profit Margin | +3.76% |
| ROE | +3.99% |
| Debt / Equity | 23.52 |
| Current Ratio | 2.42 |
| Total Cash | $132.95M |
| Total Debt | $60.13M |
| Free Cash Flow | $-184,125 |
Source: Nexqual, June 10, 2026 at 02:06 UTC.
Financial Health Score (MTLS)
Nexqual rates MTLS's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:06 UTC.
| Growth | Mixed — Revenue +0.3% YoY (annual), slow |
|---|---|
| Profitability | Solid — Gross margin 58%, operating 3% |
| Balance Sheet | Strong — $133M cash vs $60M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$184K, burning cash |
| Efficiency | Weak — ROE 4%, ROA 1.6% |
Ownership (MTLS)
| Insider Ownership | +5.30% |
|---|---|
| Institutional Ownership | +13.51% |
| Shares Outstanding | 58.18M |
| Float | 23.60M |
| Short % of Float | +1.56% |
Source: Nexqual, June 10, 2026 at 02:06 UTC.
Leadership (MTLS)
MTLS is led by Brigitte de Vet-Veithen (age 53), Chief Executive Officer, per Nexqual as of June 10, 2026 at 02:06 UTC.
| Chief Executive Officer | Brigitte de Vet-Veithen (age 53) |
|---|---|
| Founder & Chairman | Wilfried Vancraen (age 63) |
| Chief Financial Officer | Koen Berges (age 49) |
| Executive VP & COO | Johan Pauwels (age 57) |
| Chief Strategy & Technology Officer and Executive VP | Bart Van der Schueren (age 57) |
Major Backers & Investors (MTLS)
Notable institutional backers of MTLS include Disciplined Growth Investors, Inc., Rock Point Advisors, LLC, ARK Invest, according to Nexqual as of June 10, 2026 at 02:06 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Disciplined Growth Investors, Inc. | 1.92% |
| Rock Point Advisors, LLC | 1.72% |
| ARK Invest | 1.46% |
| Archon Capital Management LLC | 1.26% |
| King Luther Capital Management | 1.06% |
| Acadian Asset Management. LLC | 0.94% |
| Wells Fargo & Company | 0.6% |
| Arrowstreet Capital, Limited Partnership | 0.58% |
Source: Nexqual, June 10, 2026 at 02:06 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PRLB | Proto Labs, Inc. | USD 75.48 | ▲ 3.91% |
| SSYS | Stratasys, Ltd. | USD 8.66 | ▼ 2.15% |
| VCYT | Veracyte, Inc. | USD 49.24 | ▲ 1.05% |
| TWST | Twist Bioscience Corporation | USD 70.06 | ▲ 1.21% |
| CGEN | Compugen Ltd. | USD 2.02 | ▼ 3.81% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:06 UTC. This page is informational and not investment advice.